

Docket No. 111828-00109

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



IN RE APPLICATION OF: Siegler

SERIAL NO: 10/644,797

GAU: TBD

FILED: August 21, 2003

EXAMINER: TBD

FOR: SERUM MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AS MARKER FOR PROSTATE CANCER

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS

P.O. BOX 1450

ALEXANDRIA, VA. 22313-1450

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a copy of applicant's pending application(s) or issued patent(s) which may be related to the present application. These documents are listed on form PTO-1449, also attached.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in any counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.
- ☐ This Information Disclosure Statement is being filed within three months of the filing date of the subject patent application.
- ☒ This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits.

PETITION

- ☐ Applicant(s) hereby request consideration of the attached information. A check is attached in the amount of the Petition fee required under 37 CFR §1.17(i)(1).

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 23-2185. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

BLANK ROME LLP

Charles R. Wolfe  
Attorney of Record  
Registration No. 28,680

600 NEW HAMPSHIRE AVENUE, N.W.  
WASHINGTON, DC 20037  
TEL (202) 944-3000  
FAX (202) 572-8398



27557

PATENT TRADEMARK OFFICE

Date:

5/3/04

O8/01



Form PTO 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 111828-00109		SERIAL NO. 10/644,797		
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT K. M. Siegler				
		FILING DATE August 21, 2003		GROUP TBD		
<b>U.S. PATENT DOCUMENTS</b>						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS SUB CLASS	FILING DATE IF APPROPRIATE
	AA	6,043,044	Mar. 28, 2000	Hudson et al.	435 7.23	
	AB	5,250,297	Oct. 5, 1993	Grauer et al.	424 88	
	AC	5,614,372	Mar. 25, 1997	Lilja et al.	435 7.23	
	AD	5,654,161	Aug. 5, 1997	Tewari	435 7.23	
	AE	6,268,151	Jul. 31, 2001	Murray et al.	435 6	
	AF	6,420,188	Jul. 16, 2002	Bucala et al.	436 500	
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
<b>FOREIGN PATENT DOCUMENTS</b>						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO	
	AS					
	AT					
	AU					
	AV					
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>						
	AW	Vandenbroeck et al. 2003. Cytokine gene polymorphism in multifactorial diseases: gateways to novel targets for immunotherapy? TRENDS in Pharmacol. Sci. 24(6):284-289.				
	AX	Meyer-Siegler et al. 2002. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer. 94(5):1449-1456.				
	AY					
	AZ					
Examiner				Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						